Today, the Administration announced that the insulin products Fiasp and Novolog are included in the initial list of drugs that will be negotiated by the Centers for Medicare & Medicaid Services (CMS). While we welcome the continued focus on the need to lower the price of insulin for those enrolled in Medicare, more must be done. Access to affordable insulin is a matter of life or death for people with type 1 diabetes. JDRF is focused on expanding affordable access to insulin for everyone who needs it, regardless of insurance status. We remain committed to working on a bipartisan basis with members of Congress to pass the INSULIN Act which would cap the cost of insulin for those with commercial insurance and make other systemic reforms to address the issue.

August 29, 2023